Troubled aTyr axes 30% of its staff as it wipes a preclinical slate clean
Faced with disappointing results from its latest preclinical program, aTyr Pharma is cutting the development short and letting go around 30% of its staff.
The San Diego-based biotech $LIFE has discarded IND plans for what would have been its third clinical program, dubbed Project ORCA. In a statement, it said the restructuring and other cost-saving measures are aimed at getting its second asset, ATYR1923, on track for PhII development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.